UK markets closed

VYNE Therapeutics Inc. (VYNE)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.3300-0.0200 (-0.85%)
As of 12:18PM EDT. Market open.
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Total revenue
424
424
477
931
20,993
Cost of revenue
-
-
-
3,348
1,392
Gross profit
-
-
-
11,407
19,601
Operating expenses
Research development
16,307
16,307
18,385
19,543
43,533
Selling general and administrative
13,375
13,375
16,387
20,299
89,543
Total operating expenses
29,682
29,682
34,772
39,842
133,076
Operating income or loss
-29,258
-29,258
-34,295
-38,911
-113,475
Interest expense
-
-
0
5,610
4,390
Total other income/expenses net
1,386
1,386
363
-135
-137,961
Income before tax
-27,872
-27,872
-33,932
-44,656
-255,826
Income tax expense
0
0
13
-448
-258
Income from continuing operations
-27,872
-27,872
-33,945
-44,208
-255,568
Net income
-28,452
-28,452
-23,210
-73,329
-255,568
Net income available to common shareholders
-28,452
-28,452
-23,210
-73,329
-255,568
Basic EPS
-9.92
-
-7.28
-25.64
-141.84
Diluted EPS
-9.92
-
-7.28
-25.64
-141.84
Basic average shares
3,260
-
3,186
2,859
1,801
Diluted average shares
3,260
-
3,186
2,859
1,801